Much Ado About Not ... Enough Data: High-Dose Chemotherapy With Autologous Stem Cell Rescue for Breast Cancer (Q32125096)

6 July 2017

1 reference

title

Much ado about not...enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer (English)

1 reference

6 July 2017

Much Ado About Not ... Enough Data: High-Dose Chemotherapy With Autologous Stem Cell Rescue for Breast Cancer (English)

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

6 December 2024

0 references

J. Zujewski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9462677

6 December 2024

A. Nelson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9462677

6 December 2024

J. Abrams

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9462677

6 December 2024

language of work or name

English

0 references

publication date

1 February 1998

1 reference

6 July 2017

4 February 1998

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9462677

full work available at URL

6 December 2024

published in

Journal of the National Cancer Institute

1 reference

6 July 2017

volume

90

1 reference

6 July 2017

issue

3

1 reference

6 July 2017

page(s)

200-209

1 reference

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

6 July 2017

cites work

1 reference

9 February 2024

https://opencitations.net/index/api/v1/citations/10.1200/JCO.1995.13.10.2483

Cancer statistics, 1996.

1

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Recent trends in U.S. breast cancer incidence, survival, and mortality rates

6 December 2024

2

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Ten-year results of FAC adjuvant chemotherapy trial in breast cancer

6 December 2024

3

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

6 December 2024

4

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

6 December 2024

5

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Bone marrow autotransplantation for solid tumors--prospects

6 December 2024

8

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Dose-response in the treatment of breast cancer: a critical review

6 December 2024

9

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology

6 December 2024

11

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Acquired multicellular-mediated resistance to alkylating agents in cancer

6 December 2024

13

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents.

6 December 2024

14

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Dose-response effect of adjuvant chemotherapy in breast cancer

6 December 2024

15

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

The importance of dose intensity in chemotherapy of metastatic breast cancer

6 December 2024

16

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer

6 December 2024

17

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.

6 December 2024

18

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study

6 December 2024

19

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

6 December 2024

20

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

6 December 2024

21

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

6 December 2024

22

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Intensive regional chemotherapy of certain cancers under protection of autologous bone marrow transfusion

6 December 2024

24

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

6 December 2024

25

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer

6 December 2024

26

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

6 December 2024

27

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer

6 December 2024

28

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report

6 December 2024

29

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile

6 December 2024

31

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer

6 December 2024

32

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer

6 December 2024

33

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Patterns of failure following bone marrow transplantation for metastatic breast cancer: The role of consolidative local therapy

6 December 2024

34

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer

6 December 2024

35

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy

6 December 2024

36

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer.

6 December 2024

37

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer

6 December 2024

38

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose chemotherapy with autologous stem cell rescue in breast cancer

6 December 2024

39

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer

6 December 2024

41

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Long-term survival after autologous bone marrow transplantation for metastatic breast carcinoma

6 December 2024

43

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer

6 December 2024

44

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support

6 December 2024

46

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin

6 December 2024

47

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer

6 December 2024

48

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Tandem autotransplantation for the treatment of metastatic breast cancer

6 December 2024

49

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies

6 December 2024

50

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer

6 December 2024

51

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial

6 December 2024

52

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team

6 December 2024

54

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer

6 December 2024

55

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.

6 December 2024

56

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis

6 December 2024

58

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer

6 December 2024

59

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.

6 December 2024

60

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation

6 December 2024

61

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer

6 December 2024

62

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose chemotherapy of breast cancer: is the question answered?

6 December 2024

64

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study

6 December 2024

66

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

6 December 2024

67

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

6 December 2024

68

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base

6 December 2024

70

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

6 December 2024

71

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status

6 December 2024

73

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

6 December 2024

74

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results

6 December 2024

76

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer

6 December 2024

77

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

High-dose chemotherapy for breast cancer

6 December 2024

78

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

Out of the courtroom and into the clinic

6 December 2024

79

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.3.200

6 December 2024

Identifiers

1 reference

6 July 2017

1 reference